Biophytis to Showcase Developments at BIO International Convention

Biophytis ( (BPTSY) ) just unveiled an announcement.

On June 4, 2025, Biophytis announced its participation in the BIO International Convention, scheduled from June 16 to 19, 2025, in Boston. The company aims to showcase its latest developments, particularly its drug candidate BIO101, and explore potential partnerships with international pharmaceutical players. This participation is significant for Biophytis as it provides a platform to engage with industry leaders and potentially enhance its market positioning through collaborations.

The most recent analyst rating on (BPTSY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.

Spark’s Take on BPTSY Stock

According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.

Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.

To see Spark’s full report on BPTSY stock, click here.

More about Biophytis

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. The company’s lead drug candidate, BIO101, is a small molecule in development for muscular diseases such as sarcopenia and metabolic disorders like obesity. Biophytis is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Its shares are listed on Euronext Growth Paris and its ADS are listed on the OTC market.

Average Trading Volume: 25

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.99M

For a thorough assessment of BPTSY stock, go to TipRanks’ Stock Analysis page.